The Leipzig Prospective Drug-Eluting Balloon-Registry – Outcome of 484 Consecutive Patients Treated for Coronary In-Stent Restenosis and De Novo Lesions Using Paclitaxel-Coated Balloons –
| Autor: | Gerhard Schuler, Sven Möbius-Winkler, Sandra Erbs, Enno Boudriot, Norman Mangner, Jennifer Adam, Marcus Sandri, Michael Woinke, Axel Linke, Madlen Uhlemann |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Paclitaxel medicine.medical_treatment Myocardial Infarction Coronary Artery Disease 030204 cardiovascular system & hematology Balloon Pericardial effusion 03 medical and health sciences 0302 clinical medicine Restenosis Germany Angioplasty medicine Humans Prospective Studies Registries 030212 general & internal medicine Myocardial infarction Angioplasty Balloon Coronary Prospective cohort study Stroke Aged Aged 80 and over business.industry Graft Occlusion Vascular General Medicine Middle Aged Vascular surgery medicine.disease Surgery Female Cardiology and Cardiovascular Medicine business Follow-Up Studies |
| Zdroj: | Circulation Journal. 80:379-386 |
| ISSN: | 1347-4820 1346-9843 |
| Popis: | Background Drug-eluting balloons (DEB) are an alternative treatment of in-stent restenosis (ISR), but data regarding outcomes of DEB in de novo lesions are lacking. Methods and results We investigated the effect of DEB on target lesion revascularization (TLR), procedural complications (coronary dissection/rupture, pericardial effusion, stent thrombosis, peri-interventional NSTEMI, stroke), major adverse cardiac and cerebrovascular events (all-cause mortality, myocardial infarction, TLR, stroke) in patients with ISR and de novo lesions in an all-comers setting. Between April 2009 and October 2013, 484 consecutive patients (mean age 68.4 years; 77.9% male) were enrolled in a prospective registry. TLR rate was 4.9% at 12 months and 8.7% at long-term follow-up of 2.3 years. Subgroup analysis confirmed a TLR rate of 8.9% after DEB treatment of ISR in bare-metal stents (21/235 lesions), 13.0% in drug-eluting stents (21/161 lesions) and 0% for de novo lesions (0/76 lesions). At long-term follow-up, all-cause mortality/cardiac mortality was 8.7% (42/484)/3.3% (16/484) and MACCE rate was 18.4% (89/484 patients), with no differences between DEB for ISR compared with de novo lesions. Conclusions DEB for ISR resulted in a low rate of TLR. Our data support DEB in ISR as an effective treatment option. DEB in small coronary vessels in our limited cohort appeared to be safe. Larger, randomized trials in small coronary vessels should be undertaken to verify the long-term results of the current trial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|